

**ASX Announcement | 2 November 2023  
Visioneering Technologies (ASX:VTI)**

## Results of Special Meeting of Stockholders

**Visioneering Technologies, Inc (ASX:VTI)** ('Visioneering,' 'VTI' or 'the Company'), producer of the NaturalVue® Multifocal 1 Day Contact Lenses, today announced the results of its Special Meeting of Stockholders held today to vote on multiple resolutions. The results of the meeting are set out in the table below in accordance with ASX Listing Rule 3.13.2.

The resolutions were decided by way of a poll, with all the resolutions being passed.

<b>Holder Voting Summary</b>		The aggregate number of securities for which valid proxy votes were received prior to the meeting and for, against or abstain on a resolution were the same as the number of securities voted on the poll for each resolution. There were no proxies received for the proxy to vote at their discretion.  The resolutions were decided by a poll.
Shares Issued and Outstanding:	31,717,219	
Shares Voted:	16,439,147	
Shares Voted (%):	51.83%	

<b>Resolution</b>	<b>Vote Type</b>	<b>Voted #</b>	<b>Voted %</b>	<b>Result</b>
Item 1. Approval of variation of Convertible Notes	For Against Abstain	5,069,261 39,912 0	99.22% 0.78% 0.00%	Carried
Item 2. Issue of Shares to Dr. David J. Mazzo, Chairman of the Company	For Against Abstain	16,361,075 66,118 0	99.60% 0.40% 0.00%	Carried
Item 3. Issue of Shares to Ms. Kathleen Miller, Non-Executive Director	For Against Abstain	16,373,029 66,118 0	99.60% 0.40% 0.00%	Carried
Item 4. Issue of Shares to Mr. Andrew Silverberg, Non-Executive Director	For Against Abstain	16,373,029 66,118 0	99.60% 0.40% 0.00%	Carried
Item 5. Issue of Shares to Dr. Dwight Akerman, Non-Executive Director	For Against Abstain	16,373,029 66,118 0	99.60% 0.40% 0.00%	Carried
Item 6. Issue of Shares to Dr. Allan Rubenstein, Non-Executive Director	For Against Abstain	16,373,029 66,118 0	99.60% 0.40% 0.00%	Carried
Item 7. Grant of Options to Dr. David J. Mazzo, Chairman of the Company, for FY23	For Against Abstain	16,377,197 49,981 115	99.70% 0.30% 0.00%	Carried
Item 8. Grant of Options to Ms. Kathleen Miller, Non-Executive Director, for FY23	For Against Abstain	16,388,051 50,981 115	99.69% 0.31% 0.00%	Carried
Item 9. Grant of Options to Mr. Andrew Silverberg, Non-Executive Director, for FY23	For Against Abstain	16,388,051 50,981 115	99.69% 0.31% 0.00%	Carried

Resolution	Vote Type	Voted #	Voted %	Result
Item 10. Grant of Options to Dr. Dwight Akerman, Non-Executive Director, for FY23	For Against Abstain	16,388,051 50,981 115	99.69% 0.31% 0.00%	Carried
Item 11. Grant of Options to Dr. Allan Rubenstein, Non-Executive Director, for FY23	For Against Abstain	16,388,051 50,981 115	99.69% 0.31% 0.00%	Carried
Item 12. Grant of Restricted Stock Units to the Company's new CEO, Dr. Juan Carlos Aragón	For Against Abstain	16,384,051 55,096 0	99.66% 0.34% 0.00%	Carried
Item 13. Approval of increase in shares reserved under the 2017 Equity Incentive Plan	For Against Abstain	16,311,424 65,981 0	99.60% 0.40% 0.00%	Carried

The Company has 1,120,000 of Convertible Notes on issue with a face value of US\$1.00 each. Subject to this approval from stockholders, the Company agreed with the holders of the Convertible Notes to amend the terms such that all the notes will convert to CDIs at a conversion price of A\$0.22. The amended conversion price is more reflective of the recent trading prices (and is the same issue price as under the Rights Offering currently open and the placements to the non-executive directors) and save the Company interest and principal payments through the stated maturity date of 30 June 2024 of approximately US\$1,184,500.

VTI CEO Dr. Juan Carlos Aragón said: "The approval of these proposals by our shareholders dramatically reduces VTI's short-term cash needs while, importantly, demonstrating the confidence of our largest shareholder, Thorney Investment Group, in our overall corporate strategy and performance as it allows them to increase their equity holdings in the company measurably. With the added cash runway that this agreement provides, we can continue our great progress in the PROTECT Clinical Trial and further support our operations."

## Ends

**This release was authorized by the CEO, Dr. Juan Carlos Aragón.**

**For more information, please contact:**

<b>Company</b>	<b>Investor and media relations</b>
Brian Lane COO and CFO, Visioneering Technologies, Inc. Email: <a href="mailto:blane@vtivision.com">blane@vtivision.com</a>	Haley Chartres H^CK Tel: +61 423 139 163 Email: <a href="mailto:haley@hck.digital">haley@hck.digital</a>

## About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in presbyopia and myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Enhanced Multifocal 1-Day Contact Lens, an extended depth of focus lens that the Company believes is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit [www.vtvision.com](http://www.vtvision.com) or call +1 844-884-5367, ext. 104.

### Foreign ownership restrictions

VTI's CHESSE Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers that are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act, or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX88